Effect of Spironolactone on Treatment of Central Serous Chorioretinopathy

Effect of Spironolacton on Choroidal Vascular Index in Patients with Central Serous Chorioretinopathy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017101536801N1

Enrollment

Registered

2017-11-19

Start date

2017-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Central Serous Chorioretinopathy. Condition 2: Central Serous Chorioretinopathy. Separation of Retinal Layers Serous retinal detachment

Interventions

Intervention 1: Tablet Spironolactone 100 mg Once Daily Orally for 6 Months and macular OCT will be obtained 1 month, 3 months and 6 months after initiation of therapy. Intervention 2: Placebo ( Eye d

Treatment - Drugs

Tablet Spironolactone 100 mg Once Daily Orally for 6 Months and macular OCT will be obtained 1 month, 3 months and 6 months after initiation of therapy.

Placebo ( Eye drop Artificial tears) q6hr Topical for 6 Months and macular OCT will be obtained 1 month, 3 months and 6 months after initiation of therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients with central serous chorioretinopathy, whose condition has just been diagnosed and who have not received any treatment. Exclusion criteria: Patients whohave been received any treatment for central serous chorioretinopathy, including intravitreal injection of bevasizumab, laser therapy, photodynamic therapy, and drug treatment; Failure to refer patients for follow-up treatment; Drug-related complications requiring drug discontinuation; Disagreement with the proposed treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Macular Central Thickness. Timepoint: At the beginning - One month later - Three months later - Six months later. Method of measurement: Based on OCT, Measured as the Thickness of the Macular Center.;Choroidal Vasculai Index. Timepoint: At the beginning - One month later - Three months later - Six months later. Method of measurement: The ratio of the luminal area to the total choroid tissue in the subfovea area using the image J software.;Visual Acuity. Timepoint: At the beginning - One month later - Three months later - Six months later. Method of measurement: Snellen Chart.;Recovery. Timepoint: Six months later. Method of measurement: Increase in visual acuity or a decrease in the thickness of the macula to less than 252 micrometers, or a rise in the choroid vascular index.	—

Measure

Time frame

Macular Central Thickness. Timepoint: At the beginning - One month later - Three months later - Six months later. Method of measurement: Based on OCT, Measured as the Thickness of the Macular Center.;Choroidal Vasculai Index. Timepoint: At the beginning - One month later - Three months later - Six months later. Method of measurement: The ratio of the luminal area to the total choroid tissue in the subfovea area using the image J software.;Visual Acuity. Timepoint: At the beginning - One month later - Three months later - Six months later. Method of measurement: Snellen Chart.;Recovery. Timepoint: Six months later. Method of measurement: Increase in visual acuity or a decrease in the thickness of the macula to less than 252 micrometers, or a rise in the choroid vascular index.

—

Secondary

Measure	Time frame
Recurrence. Timepoint: At 1 year. Method of measurement: Based on OCT measurements, which, with the increase in the thickness of the macular center, precipitates as fluid re-accumulation in the sub-retinal substrate after the fluid has completely disappeared.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Ataollahi

Zahedan Universty of Medical Sciences

ataollahi.med@gmail.com+98 54 3322 4991

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026